According to reports, the world's most extensive COVID-19 vaccine study began on Monday with the help of 30,000 volunteers testing out the newly developed shots by the USA government.
There's still no guarantee that the experimental vaccine, developed by the National Institutes of Health and Moderna Inc, will really protect.
"We look forward to this trial demonstrating the potential of our vaccine to prevent COVID-19, so that we can defeat this pandemic", she continued. The makeup of the overall group of participants is meant to study not only geographical distribution, covering regions hard-hit by the virus and those with less severe outbreaks, but also to represent a wide sample when it comes to demographics of those participating.
Moderna Inc says it has received an additional $472m from the United States government's Biomedical Advanced Research and Development Authority (BARDA) to support the development of its novel coronavirus vaccine.
Just 65 days later in March, the NIH-made vaccine was tested in people.
He said 150 cases of infection "need to occur ... to statistically be able to compare the placebo ... and declare whether the vaccine" provides adequate protection.
The government announced last week that it had reached a $1.95 billion deal to buy 100 million doses of Pfizer's vaccine by the year's end, but only if the trial proves it safe and effective.
Unlike some other companies that are developing vaccines using live or inactivated viruses, Moderna's vaccine uses messenger RNA (mRNA), which are cells used to build proteins.
According to Swaroop, the DBT is part of any COVID-19 vaccine effort in India whether it is funding, whether it is facilitating the regulatory clearances or whether it is giving them access to different networks which exist within the country. He said that emerging data from the trial should be available in November or December, and insisted that despite the speed of the development, "there is no compromise at all with regard to safety or scientific integrity". In India, two indigenous vaccines one by Zydus Cadila and the other by Bharat Biotech have reached the stage of phase one of human trials.
And their main goal will be to see if significantly fewer vaccinated people contract COVID-19, to determine whether the vaccine can prevent the illness.
While AstraZeneca and Johnson & Johnson pledged they would produce hundreds of millions of doses of their vaccines at no profit to themselves, Hoge said, "we will not sell it at cost". Up to 30,000 volunteers will be assigned to one of two groups.
On July 20, scientists announced that the coronavirus vaccine developed by Oxford University appears safe and induces a strong immune response within the body after the first phase of "promising" human trials against the deadly disease that has infected over 1.45 crore people across the world and claimed more than six lakh lives.